vTv Therapeutics (VTVT) announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer, effective immediately. Dr. Tung joins the Company with 20 years of diversified finance, corporate strategy, investor relations, and business development experience in the biopharmaceutical industry.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTVT:
- vTv Therapeutics Highlights Cadisegliatin’s Potential for Diabetes
- Buy Rating for vTv Therapeutics: Promising Potential of Cadisegliatin in Type 1 Diabetes Treatment
- vTv Therapeutics reports Q1 EPS (77c), consensus (81c)
- vTv Therapeutics reports reinitiation of screening in CATT1 Phase 3 trial
- VTVT Upcoming Earnings Report: What to Expect?